Anti-dengue vaccines and antibodies

A composition comprising an adjuvant and a compound that binds to an E-Dimer Epitope (EDE), wherein the compound is an antibody comprising a heavy chain comprising CDR regions and light chain comprising CDR regions, or antigen binding portion thereof,

• wherein the antibody, or antigen binding portion thereof, comprises:
• a) a heavy chain variable region comprising the amino acid sequences SEQ ID NO:
• 5, 6 and 7 and a light chain variable region comprising the amino acid sequences SEQ ID NO:
• 17, 18 and 19;
• or
• b) a heavy chain variable region comprising the amino acid sequences SEQ ID NO:
• 8, 9 and 10 and a light chain variable region comprising the amino acid sequences SEQ ID NO:
• 20, 21 and 22;
• or
• c) a heavy chain variable region comprising the amino acid sequences SEQ ID NO:
• 11, 12 and 13 and a light chain variable region comprising the amino acid sequences SEQ ID NO:
• 23, 24 and 25;
• or
• d) a heavy chain variable region comprising the amino acid sequences SEQ ID NO:
• 14, 15, and 16 and a light chain variable region comprising the amino acid sequences SEQ ID NO:
• 26, 27 and 28;
• wherein the EDE comprises a stabilized recombinant dengue virus envelope glycoprotein E ectodomain (sE) dimer, a dimer of Envelope proteins, or the antigenic portion thereof, or consecutive or non-consecutive residues of the envelope polypeptide dimer, held within a heterologous scaffold protein, and
• wherein said antibody or fragment thereof binds the five polypeptide segments of the dengue virus glycoprotein E ectodomain consisting of the residues 67-74, residues 97-106, residues 307-314, residues 148-159 and residues 243-251, wherein the amino acid residue position of each sE monomer is numbered according to SEQ ID NO:
• 132, SEQ ID NO:
• 133, SEQ ID NO:
• 134, and SEQ ID NO:
• 135.